cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response
AbstractThe last two decades have witnessed enormous growth in the field of cancer immunity. Mechanistic insights of cancer immunoediting have not only enhanced our understanding but also paved the way to target and/or harness the innate immune system to combat cancer, called cancer immunotherapy. Cyclic GMP-AMP synthase (cGAS)/Stimulator of interferon genes(STING) pathway has recently emerged as nodal player in cancer immunity and is currently being explored as potential therapeutic target. Although therapeutic activation of this pathway has shown promising anti-tumor effects in vivo, evidence also indicates the role of this pathway in inflammation mediated carcinogenesis. This review highlights our current understanding of cGAS/STING pathway in cancer, its therapeutic targeting and potential alternate approaches to target this pathway. Optimal therapeutic targeting and artificial tunability of this pathway still demand in depth understanding of cGAS/STING pathway regulation and homeostasis. View Full-Text
Share & Cite This Article
Bose, D. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response. Int. J. Mol. Sci. 2017, 18, 2456.
Bose D. cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response. International Journal of Molecular Sciences. 2017; 18(11):2456.Chicago/Turabian Style
Bose, Debojit. 2017. "cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response." Int. J. Mol. Sci. 18, no. 11: 2456.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.